China & United States — Food and Drug Administration
16 shared events · Importance 9 · Last updated Jun 18, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
China: China is the target market for Lerociclib, with an estimated 400 million individuals suffering from dyslipidemia and a significant unmet medical need for lipid-lowering treatments.
United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) has already approved Lerociclib, indicating its efficacy and safety profile, which supports its regulatory review in other regions.
Jun 26, 2026 · 8 articles
Tech
China: China is referenced for its high prevalence of cervical cancer cases, underscoring the significant market need for United Therapeutics' therapy in the Asia-Pacific region.
United States — Food and Drug Administration: The United States — Food and Drug Administration is mentioned as the body that has not yet approved the investigational therapy, indicating future regulatory hurdles for United Therapeutics.
May 19, 2026 · 7 articles
NEWSDESK
Explore this relationship live
Track how China and United States — Food and Drug Administration interact across events, view sentiment trends, and discover connected entities.
Open Dashboard